USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...

With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

Improvements in 2 patient-reported outcome measures were observed among patients with psoriasis treated with deucravacitinib vs placebo or apremilast.

NexoBrid Approval Expanded to Include Pediatric Burn Patients Otezla (apremilast) Phosphodiesterase type 4 inhibitor Treatment of pediatric patients 6 years of age and older weighing at least 20kg ...

Since Sunday, Tropical Storm Enteng (international name: Yagi) has brought rains and caused heavy flooding in Metro Manila and its neighboring cities, with Signal No. 2 raised in nine areas in Luzon.

The Food and Drug Administration (FDA) has expanded the approval of apremilast and included treatment of children 6 years of age and older weighing at least 20kg with moderate to severe plaque ...

Study participants were randomly assigned to receive apremilast (n=163) or placebo (n=82) for 16 weeks. For the first time, children and adolescents with moderate to severe plaque psoriasis and their ...